

**RECEIVED**

January 12, 2001

Micheline Gravelle B.Sc., M.Sc. (Immunol.)
416 957 1682 mgravelle@bereskinparr.com

JAN 18 2001

Your Reference: 09/645,594
Our Reference: 11157-14

TECH CENTER 1600/2900

Commissioner for Patents and Trademarks
Washington, D.C. 20231
U.S.A.

Dear Sir:

Re: FILING OF AN INFORMATION DISCLOSURE STATEMENT**United States Patent Application No. 09/645,594****Entitled: Use of Charged Dextran as a Mucoactive Agent and Methods
and Pharmaceutical Compositions Relating Thereto****Inventors: Malcolm King****Filing Date: August 25, 2000****Grp Art Unit: 1615**

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

MALCOLM KING



Micheline Gravelle
Registration No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2

Tel. (416) 364-7311